Zoetis Inc. $ZTS Shares Acquired by First National Advisers LLC

First National Advisers LLC grew its holdings in Zoetis Inc. (NYSE:ZTS) by 7.8% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 30,555 shares of the company’s stock after acquiring an additional 2,212 shares during the quarter. Zoetis comprises 0.7% of First National Advisers LLC’s investment portfolio, making the stock its 29th biggest holding. First National Advisers LLC’s holdings in Zoetis were worth $4,766,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in ZTS. Norges Bank purchased a new position in Zoetis in the second quarter valued at approximately $809,491,000. Nuveen LLC purchased a new position in shares of Zoetis in the 1st quarter valued at $616,375,000. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in Zoetis by 113.0% during the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,761,920 shares of the company’s stock worth $586,671,000 after acquiring an additional 1,995,491 shares in the last quarter. Polen Capital Management LLC lifted its position in Zoetis by 17.6% in the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock valued at $1,448,401,000 after acquiring an additional 1,313,653 shares during the last quarter. Finally, Impax Asset Management Group plc lifted its position in Zoetis by 362.6% in the second quarter. Impax Asset Management Group plc now owns 1,176,996 shares of the company’s stock valued at $182,705,000 after acquiring an additional 922,589 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Trading Up 0.4%

NYSE ZTS opened at $128.18 on Friday. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The firm has a 50-day moving average price of $135.77 and a 200 day moving average price of $149.09. The stock has a market capitalization of $56.49 billion, a P/E ratio of 22.06, a P/E/G ratio of 2.31 and a beta of 0.90. Zoetis Inc. has a 52-week low of $115.25 and a 52-week high of $181.85.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.42 billion. During the same quarter in the prior year, the company posted $1.58 earnings per share. Zoetis’s quarterly revenue was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.6%. The ex-dividend date is Friday, October 31st. Zoetis’s dividend payout ratio (DPR) is presently 33.67%.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on ZTS. Stifel Nicolaus dropped their price objective on Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a report on Tuesday, November 18th. Morgan Stanley decreased their target price on Zoetis from $211.00 to $175.00 and set an “overweight” rating for the company in a research report on Monday, November 10th. Piper Sandler lifted their price target on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. BTIG Research decreased their price objective on Zoetis from $200.00 to $160.00 and set a “buy” rating for the company in a report on Wednesday, November 12th. Finally, UBS Group lowered their target price on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 5th. Six investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $178.89.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.